Single nucleotide polymorphisms: impact on susceptibility to chemotherapy in patients with colorectal cancer.

IF 2.4 Q3 MEDICINE, RESEARCH & EXPERIMENTAL

Future Science OA Pub Date : 2024-12-01 Epub Date: 2024-11-22 DOI:10.1080/20565623.2024.2428077

M Angeles Vaz-Salgado, Victor Albarran, Javier Pozas, Reyes Ferreiro, Vanessa Pachón, Federico Longo, Mercedes Rodriguez, Emma Barreto, Julie Earl

{"title":"Single nucleotide polymorphisms: impact on susceptibility to chemotherapy in patients with colorectal cancer.","authors":"M Angeles Vaz-Salgado, Victor Albarran, Javier Pozas, Reyes Ferreiro, Vanessa Pachón, Federico Longo, Mercedes Rodriguez, Emma Barreto, Julie Earl","doi":"10.1080/20565623.2024.2428077","DOIUrl":null,"url":null,"abstract":"Background: Single-nucleotide polymorphisms (SNPs) in enzyme-coding genes play a role in susceptibility to anti-cancer therapy.Materials & methods: A prospective study was performed of the relationship between enzyme activity and treatment response, drug toxicity and hypersensitivity reactions in 51 patients with colorectal cancer treated with fluoropyrimidine-based chemotherapy. SNP analysis was performed in 22 enzyme-coding genes with a previously described role in treatment efficacy.Results: SLC6 and MTHR enzyme activity was related with rates of progressive disease, GSTP1 activity with anti-EGFR antibodies-related skin toxicity, CYP3A5 and MTHR with chemotherapy dose reduction, CYP2B6, IL10, MTHR and TYMS activity with the risk of drug hypersensitivity reactions.Conclusion: Pharmacogenetics is a valuable predictive marker in oncology, related to chemotherapy treatment response, toxicity and hypersensitivity.","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"10 1","pages":"2428077"},"PeriodicalIF":2.4000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11587850/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future Science OA","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/20565623.2024.2428077","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/11/22 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Single-nucleotide polymorphisms (SNPs) in enzyme-coding genes play a role in susceptibility to anti-cancer therapy.

Materials & methods: A prospective study was performed of the relationship between enzyme activity and treatment response, drug toxicity and hypersensitivity reactions in 51 patients with colorectal cancer treated with fluoropyrimidine-based chemotherapy. SNP analysis was performed in 22 enzyme-coding genes with a previously described role in treatment efficacy.

Results: SLC6 and MTHR enzyme activity was related with rates of progressive disease, GSTP1 activity with anti-EGFR antibodies-related skin toxicity, CYP3A5 and MTHR with chemotherapy dose reduction, CYP2B6, IL10, MTHR and TYMS activity with the risk of drug hypersensitivity reactions.

Conclusion: Pharmacogenetics is a valuable predictive marker in oncology, related to chemotherapy treatment response, toxicity and hypersensitivity.

查看原文本刊更多论文

单核苷酸多态性：对结直肠癌患者化疗敏感性的影响。

背景：酶编码基因中的单核苷酸多态性（SNPs）在抗癌治疗的易感性中发挥作用：对51名接受氟嘧啶类化疗的结直肠癌患者的酶活性与治疗反应、药物毒性和超敏反应之间的关系进行了前瞻性研究。研究对 22 个酶编码基因中的 SNP 进行了分析，这些基因以前曾被描述过在疗效中的作用：结果：SLC6和MTHR酶活性与疾病进展率有关，GSTP1活性与抗EGFR抗体相关的皮肤毒性有关，CYP3A5和MTHR与化疗剂量减少有关，CYP2B6、IL10、MTHR和TYMS活性与药物超敏反应风险有关：药物遗传学是肿瘤学中与化疗反应、毒性和超敏反应相关的重要预测指标。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Future Science OA MEDICINE, RESEARCH & EXPERIMENTAL-

CiteScore

5.00

自引率

4.00%

发文量

审稿时长

13 weeks

期刊介绍： Future Science OA is an online, open access, peer-reviewed title from the Future Science Group. The journal covers research and discussion related to advances in biotechnology, medicine and health. The journal embraces the importance of publishing all good-quality research with the potential to further the progress of research in these fields. All original research articles will be considered that are within the journal''s scope, and have been conducted with scientific rigour and research integrity. The journal also features review articles, editorials and perspectives, providing readers with a leading source of commentary and analysis. Submissions of the following article types will be considered: -Research articles -Preliminary communications -Short communications -Methodologies -Trial design articles -Trial results (including early-phase and negative studies) -Reviews -Perspectives -Commentaries